ESSA Pharmaceuticals, Inc.

400 Oyster Point Blvd.
Suite 520
South San Francisco
United States

Tel: 650-449-8400
Fax: 650-449-8401

Show jobs for this employer

About ESSA Pharmaceuticals, Inc.

ESSA is a pre-clinical stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies, by disrupting the androgen receptor ("AR") signaling pathway that drives prostate cancer growth and by preventing AR transcriptional activity by binding selectively to the N-terminal domain ("NTD") of the AR. A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009.

Stock Symbol: EPIX

Stock Exchange: Nasdaq

84 articles with ESSA Pharmaceuticals, Inc.